ArticleCureus2025
Xywav: A Treatment Option for Idiopathic Hypersomnia in Down Syndrome.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic hypersomnia (IH) is a rare and chronic neurological sleep disorder in which patients experience excessive daytime sleepiness (EDS) with symptoms often overlapping with numerous other sleep conditions. This diagnostic overlap can further delay accurate diagnosis and treatment, which poses significant challenges for both patients and clinicians. Additionally, vulnerable populations, such as those with Down syndrome (DS), face further obstacles given the absence of therapeutic studies addressing IH in DS. This case presentation highlights the case of a 40-year-old female patient with DS who suffered from substantial hypersomnolence and had responded favorably to a supervised trial of Xywav (calcium, magnesium, potassium, or sodium oxybates), making this the first known case presentation to demonstrate an effective treatment strategy for this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.